Neurocrine Biosciences, Inc. (NBIX) Reports In-Line Q4 EPS of $0.02, Offers Poor FY12 Guidance
NBIX Hot Sheet
EPS Growth %: -120.0%Financial Fact:
Income (loss) from operations: -1.79M
Today's EPS Names:
TARO, BRLI, TLB, More
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported Q4 EPS of $0.02, in-line with the analyst estimate of $0.02. Revenue for the quarter came in at $11.1 million versus the consensus estimate of $12.08 million.
Neurocrine Biosciences, Inc. sees FY2012 EPS of $-0.21-$-0.14, versus the consensus of $0.02. Neurocrine Biosciences, Inc. sees FY2012 revenue of $40-$45 million, versus the consensus of $51.72 million. The Company expects to have a net cash burn from operations of approximately $40 to $45 million in 2012.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Neurocrine Biosciences, Inc. sees FY2012 EPS of $-0.21-$-0.14, versus the consensus of $0.02. Neurocrine Biosciences, Inc. sees FY2012 revenue of $40-$45 million, versus the consensus of $51.72 million. The Company expects to have a net cash burn from operations of approximately $40 to $45 million in 2012.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Jiayuan.com (DATE) Reports In-Line Q1 EPS of 5c; Guides Q2 Revs
- UPDATE: NetApp, Inc. (NTAP) Tops Q4 EPS by 3c; Guides Q1 Lower
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
